Compare Transocean Ltd (RIG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs Tango Therapeutics Inc. — how do they compare? Transocean Ltd trades at $5.6 (market cap $6.31B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Transocean Ltd is the larger of the two by market cap, and Transocean Ltd is more actively traded (37,551,905 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold Transocean Ltd for 18 Days and Tango Therapeutics Inc. for 0 Days on average.
| RIG | TNGX | |
|---|---|---|
Market Cap | $6.31B | $3.75B |
Volume | 37,551,905 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $7.58 | $32.90 |
52-Week Low | $3.23 | $7.50 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $10.92B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.65, up 0.89% today, with a bullish technical signal from moving averages. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses. Recent contract wins including an $80M Equatorial Guinea deal and DOJ approval for the $5.8B Valaris acquisition provide positive catalysts. Cash flow improvement is notable with operating cash flow reaching $995M in 2026.
RIG presents a speculative opportunity driven by offshore cycle strength and deleveraging potential, but high debt levels and negative profitability pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about contract backlog versus concerns about execution and financial leverage. The stock's upside depends on successful debt reduction and sustained offshore drilling demand.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
